S1152
Clinical - Urology
ESTRO 2026
response (p<0.001) independently predicted LC.
Patient characteristics are shown on Table1.
Grade ≥ 3 acute genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 5% and 4.1% of patients, respectively. Grade ≥ 3 late GU and GI toxicities were observed in 8.1% and 9% of patients. No treatment- related mortality was recorded. Conclusion: Over a 20-year period, CBAHRT demonstrated durable bladder preservation and sustained LC with acceptable late toxicity, reinforcing its role as a practical organ-sparing option in selected patients. These long-term real-world data show outcomes comparable to cystectomy and concurrent chemoradiation while maintaining bladder function, representing one of the longest follow-up analyses of bladder-preserving RT without chemotherapy. References: 1. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Compérat, Eva et al. The Lancet, Volume 400, Issue 10364, 1712 - 1721, 20222. Long-term Outcomes in Treatment of Invasive Bladder Cancer With Concomitant Boost and Accelerated Hyperfractionated Radiation Therapy. Canyilmaz, Emine et al. International Journal of Radiation Oncology, Biology, Physics, Volume 90, Issue 3, 562 - 569, 2014 Keywords: Bladder cancer, radiotherapy, concomitant boost Digital Poster 744 Benefit of Prophylactic Pelvic Irradiation in Intermediate-Risk Prostate Cancer: A Multicenter Retrospective Study (iPPAPI) Charles Raynaud 1 , Rafik Nebbache 2 , Yazid Belkacemi 3 , Cyrus Chargari 4 , Catherine Durdux 1 , Christophe Hennequin 5 , Florence Huguet 6 , Laurent Quero 5 , Jean- Emmanuel Bibault 1 1 Radiotherapy, European Hospital Georges Pompidou, Paris, France. 2 Radiotherapy, Gustave Roussy Institute, Villejuif, France. 3 Radiotherapy, Mondor Hospital, Créteil, France. 4 Radiotherapy, Pitié-Salpêtrière Hospital, Paris, France. 5 Radiotherapy, Saint Louis Hospital, Paris, France. 6 Radiotherapy, Tenon Hospital, Paris, France Purpose/Objective: Prostate cancer (PCa) is the most common urologic malignancy in men, with most cases diagnosed at a localized stage. The benefit of whole-pelvic
The median OS was 39.7 months (95% CI: 32.4–47.0), with 5-, 10-, 15-, and 20-year OS rates of 38.8%, 21.6%, 15.1%, and 15.1%, respectively (Figure1.). Multivariate analysis identified T stage (p=0.007) and treatment response (p<0.001) as independent predictors of overall survival.The median CSS was 58.9 months (95% CI: 43.5–74.3), with 5-, 10-, 15-, and 20-year CSS rates of 49.8%, 34.4%, 29.9%, and 29.9%, respectively (Figure2.). T stage (p=0.001), sex (p=0.046), and treatment response (p<0.001) were significant predictors in multivariate analysis.The median LC was 149.3 months (95% CI: 96.8–201.8), with 5-, 10-, 15-, and 20-year LC rates of 62.5%, 56.8%, 48.5%, and 25.9%, respectively (Figure3.). T stage (p=0.025), ureteral obstruction (p=0.006), and treatment
Made with FlippingBook - Share PDF online